Table 1

Summary of primary studies with HIV/HCV biomarkers
Study Information Coverage Pre-Implementation and Expansion Post-Implementation and Expansion
Investigator Location Study Design Syringes per PWID/Year1 Year (n) HIV prev. HCV prev. Estimated HIVinc.2 HCV inc. Year (n) HIV prev.3 HCV prev.3 Estimated HIVinc.2 HCV inc.
Gray 1998 [25] Chiang Rai, Thailand Time Series Cross Sectional 150-160 1993 46 33% 1996 132 18% (15%)
Caiaffa 2003 [26] Porto Alegre, Brazil Pre-Post Study Comparison 6-20 1998 137 49% 2001 255 64.3% (+16%)
Wu 2007 [27] Dagou, China Pre-Post Study Comparison 290-300 2002 235 40% 99% 2003 226 34% (6%) 89% (10%)
Luzhai, China Pre-Post Study Comparison 140-150 2002 194 56% 89% 2003 219 53% (3%) 85% (4%)
Azim 2008 [28] Dhaka, Bangladesh Time Series Cross Sectional 285-344 1990 418 2% 67% 2006 1092 7% (+5%) 57% (10%)
Azim 2009 [29] Dhaka, Bangladesh Time Series Cross Sectional 285-344 1999 418 1.2/100 PY 2007 1045 1.3/100 PY
Uuskula 2011 [30] Tallinn, Estonia Time Series Cross Sectional 23-78 2005 350 54% 20.9/100 PY 2009 327 50% (4%) 9/100 PY
Hammett 2012 [31] Ning Ming, China Time Series Cross Sectional 20-30 2002 290 17% 12/100 PY 2008 187 11% (6%) 11/100 PY
Lang Son, Vietnam Time Series Cross Sectional 20-30 2002 342 46% 22/100 PY 2009 185 23% (23%) 3/100 PY

1. Syringes per PWID/Year are given as a range based on the first and last date of data collection in each primary study location.

2. Among new PWID (persons who had begun injecting in the previous 3 years, assumed to be HIV negative when they began injecting).

3. Post Implementation columns include follow-up biomarker information in addition to the difference from baseline to follow-up.

Des Jarlais et al.

Des Jarlais et al. BMC Public Health 2013 13:53   doi:10.1186/1471-2458-13-53

Open Data